| |
| |
|
| Insider
Information: |
Witte Owen N. |
| Relationship: |
|
| City: |
Santa Monica |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
292,832 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
292,832 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Kite Pharma, Inc. |
KITE |
Director |
2017-10-03 |
0 |
2017-03-14 |
0 |
Premium* |
|
|
Allogene Therapeutics, Inc. |
ALLO |
|
2023-06-13 |
292,832 |
2018-10-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
20 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALLO |
Allogene Therapeutics, In... |
|
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
74,561 |
292,832 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
Director |
– • – |
2022-08-12 |
4 |
S |
$17.25 |
$86,250 |
D/D |
(5,000) |
218,271 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
Director |
– • – |
2022-08-11 |
4 |
S |
$16.50 |
$165,000 |
D/D |
(10,000) |
223,271 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2022-06-22 |
4 |
S |
$11.76 |
$117,600 |
D/D |
(10,000) |
233,271 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,089 |
243,271 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2021-09-09 |
4 |
S |
$25.54 |
$127,700 |
D/D |
(5,000) |
221,182 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2021-08-20 |
4 |
S |
$23.24 |
$234,700 |
D/D |
(10,000) |
226,182 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2021-06-09 |
4 |
S |
$25.05 |
$249,723 |
D/D |
(9,969) |
236,182 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
9,969 |
246,151 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
Director |
– • – |
2018-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
37,432 |
236,182 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
Director |
– • – |
2018-10-15 |
4 |
B |
$18.00 |
$270,000 |
D/D |
15,000 |
198,750 |
2.39 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-10-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,715) |
0 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-10-03 |
4 |
D |
$180.00 |
$10,536,300 |
D/D |
(58,535) |
5,715 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-09-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,000 |
64,250 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-06-26 |
4 |
AS |
$100.60 |
$1,257,500 |
D/D |
(12,500) |
76,250 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-06-23 |
4 |
OE |
$6.89 |
$225,000 |
D/D |
12,500 |
101,250 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-06-23 |
4 |
AS |
$100.00 |
$1,250,000 |
D/D |
(12,500) |
88,750 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,410 |
88,750 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-03-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
81,650 |
|
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,690 |
86,340 |
0 |
- |
|
20 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
